tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Meet Alterity Therapeutics: Fly exclusive interview with CEO David Stamler
PremiumThe FlyMeet Alterity Therapeutics: Fly exclusive interview with CEO David Stamler
29d ago
Alterity Therapeutics presents analyses related to OH from ATH434-201 trial
Premium
The Fly
Alterity Therapeutics presents analyses related to OH from ATH434-201 trial
1M ago
Alterity Therapeutics reports cash balance of A$54.46M as of September 30
Premium
The Fly
Alterity Therapeutics reports cash balance of A$54.46M as of September 30
2M ago
Alterity Therapeutics Sets AGM and Director Nomination Dates
PremiumCompany AnnouncementsAlterity Therapeutics Sets AGM and Director Nomination Dates
3M ago
Alterity Therapeutics presents ATH434-201 Phase 2 data
Premium
The Fly
Alterity Therapeutics presents ATH434-201 Phase 2 data
3M ago
Alterity Therapeutics raises A$20M in strategic placement
Premium
The Fly
Alterity Therapeutics raises A$20M in strategic placement
3M ago
Buy Rating for Alterity Therapeutics: Promising Phase 2 Results and Investment Opportunity Amid Stock Price Dip
PremiumRatingsBuy Rating for Alterity Therapeutics: Promising Phase 2 Results and Investment Opportunity Amid Stock Price Dip
5M ago
Alterity Therapeutics reports topline data from open-label Phase 2 ATH434 trial
Premium
The Fly
Alterity Therapeutics reports topline data from open-label Phase 2 ATH434 trial
5M ago
Alterity Therapeutics announces publication on MRI endpoint from bioMUSE study
Premium
The Fly
Alterity Therapeutics announces publication on MRI endpoint from bioMUSE study
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100